Stay updated on Milademetan Safety in AML/MDS Clinical Trial
Sign up to get notified when there's something new on the Milademetan Safety in AML/MDS Clinical Trial page.

Latest updates to the Milademetan Safety in AML/MDS Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe clinical trial record for milademetan in AML or high-risk MDS is displayed, with study details, participant criteria, outcomes, and data-sharing and document information.SummaryDifference70%

- Check21 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0; the study record remains inaccessible behind a 403 error.SummaryDifference0.2%

- Check28 days agoChange DetectedA site-wide NIH notice announces updates and FAQs about the transition from “Artificial Intelligence” to “Super Intelligence” terminology.SummaryDifference1%

- Check34 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check63 days agoChange DetectedThe study page now shows a 403 error, replacing the previous detailed study content with an access-denied message. The change removes the rich study data and presents an error state instead.SummaryDifference21%

Stay in the know with updates to Milademetan Safety in AML/MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Milademetan Safety in AML/MDS Clinical Trial page.